Hugues de Lavallade

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib

David Marín, Alexandra Bazeos, François-Xavier Mahon et al. · Journal of Clinical Oncology · 2010 · 901 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society

Alexander R. Lyon, Susan Dent, Susannah Stanway et al. · European Journal of Heart Failure · 2020 · 770 citations · Full text

Medicine, Cardiology, Oncology +16

Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis

Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad et al. · Journal of Clinical Oncology · 2008 · 556 citations

Medicine, Hematology, Pharmacology +8

European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor

David Marín, Dragana Milojković, Eduardo Olavarría et al. · Blood · 2008 · 328 citations · Full text

Medicine, Hematology, Pharmacotherapy +13

Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia

Kate Stringaris, Takuya Sekine, A. Khoder et al. · Haematologica · 2014 · 232 citations · Full text

Life Sciences, Immunology, Oncology +17